DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Schizophrenia – Unmet Need – Unmet Need – Cognitive Impairment Associated with Schizophrenia (US/EU)
CIAS (e.g., impaired attention / vigilance, memory, and/or executive function) negatively impacts patients’ daily activities, occupational and social functioning, and adherence to antipsychotic…
Paroxysmal Nocturnal Hemoglobinuria | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2024
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…
Myasthenia Gravis – Current Treatment – Current Treatment: Physician Insights – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder primarily caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Current Treatment: Physician Insights – Diabetic Macular Edema / Diabetic Retinopathy (US)
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels and resulting in vision loss and blindness if left untreated. The VEGF…
Chronic Kidney Disease – Current Treatment – Current Treatment: Physician Insights – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. RAAS inhibitors are cornerstones of CKD treatment. SGLT-2…
Schizophrenia – Current Treatment – Current Treatment: Physician Insights – Schizophrenia (US)
In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [LAI]) formulations are the mainstay of schizophrenia treatment. However, the dearth of…